Robert Adelman
QuietNamed in filings at Venbio SelectOn the current fund
- Board seats filed
- 5
Named in filings at Venbio SelectOn the current fund
all filings on record
last 24 months
from a verified or cited source
| TP Therapeutics | Biotech & pharma | October 2018 | Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis, Venbio Global Strategic, Vivo Innovation |
| Apellis Pharmaceuticals | Biotech & pharma | December 2015 | Sofinnova Venture Partners, Venbio Global Strategic |
| PRECISION BIOSCIENCES | Not yet classified | April 2015 | Venbio Global Strategic |
| Metacrine | Biotech & pharma | January 2015 | ARCH Venture Partners, Polaris Partners, Venbio Global Strategic |
| Solstice Biologics | Not yet classified | September 2014 | Venbio Global Strategic |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Robert Adelman on the board, based on 3 filed seats with a verified or cited source.
2 more filed seats not yet classified, left out of the shares above.